Mounjaro developer Lilly to invest in Korea as AI drug development hub
ACS Central Science | Researchers from Insilico Medicine and Lilly publish foundational vision for fully autonomous “Prompt-to-Drug” pharmaceutical R&D - EurekAlert!
Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity
Marcos Vilela wins Lilly Research Award for Doctoral Students - EurekAlert
